Literature DB >> 25365973

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.

Fred Poordad1, Kosh Agarwal2, Ziad Younes3, Daniel Cohen4, Wangang Xie4, Thomas Podsadecki4.   

Abstract

In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  concordance; direct-acting antivirals; hepatitis C; sustained virologic response

Mesh：

Substances：

Year:  2014        PMID： 25365973     DOI： 10.1093/cid/ciu865

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Care of Patients Following Cure of Hepatitis C Virus Infection.

Authors:  Norah A Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-11

Review 2.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

Review 3.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06

4.  HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.

Authors:  Daniel Radwan; Edward Cachay; Oluwaseun Falade-Nwulia; Richard D Moore; Ryan Westergaard; William Christopher Mathews; Judith Aberg; Laura Cheever; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

5.  Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

Authors:  Peter Ferenci; Stefan Bourgeois; Peter Buggisch; Suzanne Norris; Manuela Curescu; Dominique Larrey; Fiona Marra; Henning Kleine; Patrick Dorr; Mariem Charafeddine; Eric Crown; Mark Bondin; David Back; Robert Flisiak
Journal:  J Viral Hepat       Date:  2019-03-05       Impact factor: 3.728

6.  Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection.

Authors:  Lisette A P Krassenburg; Wayel R Zanjir; Firas Georgie; Emily Stotland; Harry L A Janssen; Bettina E Hansen; Jordan J Feld
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

7.  Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.

Authors:  Lourdes Domínguez-Domínguez; Otilia Bisbal; Mariano Matarranz; María Lagarde; Óscar Pinar; Asunción Hernando; Carlos Lumbreras; Rafael Rubio; Federico Pulido
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-28       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.